Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Shares Outstanding (Weighted Average) (2022 - 2025)

Corvus Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 4 years, most recently at $77.6 million for Q3 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $77.6 million for Q3 2025, up 32.65% from a year ago — trailing twelve months through Sep 2025 was $77.6 million (up 32.65% YoY), and the annual figure for FY2024 was $61.0 million, up 26.99%.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $77.6 million at Corvus Pharmaceuticals, up from $75.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for CRVS hit a ceiling of $77.6 million in Q3 2025 and a floor of $46.6 million in Q1 2022.
  • Median Shares Outstanding (Weighted Average) over the past 4 years was $49.0 million (2023), compared with a mean of $55.0 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): rose 0.01% in 2023 and later surged 47.08% in 2025.
  • Corvus Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $46.6 million in 2022, then grew by 3.16% to $48.0 million in 2023, then rose by 26.99% to $61.0 million in 2024, then rose by 27.27% to $77.6 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $77.6 million (Q3 2025), $75.0 million (Q2 2025), and $72.1 million (Q1 2025) per Business Quant data.